SAN DIEGO, June 24 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI) announces the election of the Company's Board
of Directors at its Annual Meeting of Shareholders. Elected to initial terms
were Donald Kaplan, Ph.D., President and Chief Operating Officer, Protein
Polymer Technologies, Inc., Steven M. Lamon, and Steve Peltzman. Reelected to
the Company's Board of Directors were:  Edward G. Cape, Ph.D. Managing Partner
of the Saphire Group LLC; Kerry L. Kuhn, M.D., a Partner in the Omega
Obstetrics and Gynecology Center, Coral Springs, Florida; J. Thomas Parmeter,
Ph.D., Chairman and Chief Executive Officer, Protein Polymer Technologies,
Inc.; and George R. Walker, Vice President-Finance (retired), Esso Europe. All
Directors are elected to annual terms.
    In other business, stockholders also ratified Peterson & Company, LLP, as
the Company's independent public accountants for the 2004 fiscal year.
    Dr. Donald S. Kaplan, recently named President and Chief Operating Officer
of Protein Polymer Technologies, Inc., is the founder and has been the
president of Matrix Technology since 2001, a start-up medical device
development company.  From 1998 to 2000 Dr. Kaplan was a chief consultant to
International Surgical Technology Inc., a surgical device start-up company.
From 1980 to 1995, Dr. Kaplan was employed by the United States SurgicaL
Corporation, initially as Vice President, Materials Science, and from 1992 to
1995 as Senior Vice President for Operations and Technology.
    Mr. Steven M. Lamon currently serves as a consultant to several
educational, religious and municipal organizations and serves on the board of
directors of two privately-held companies. From 1976 to January 2003, Mr.
Lamon was employed by Merrill Lynch, initially as an equity institutional
salesman and from 1984 to 2002 as Head of the Chicago Institutional Equity
Sales desk and Director of Merrill Lynch Capital Markets.
    Mr. Steve Peltzman currently serves on the board of directors of
Cytomatrix, LLC, a biotherapeutics company and Select Therapeutics, Inc. From
1991 to 1997 Mr. Peltzman served initially as Executive Vice President and
Chief Operating Officer and from 1994 to 1997 as president and chief operating
officer of OSI Pharmaceuticals, Inc., and from 1997 to 1999 as a director of
OSI Pharmaceuticals, Inc.  From 1984 to 1991, Mr. Peltzman was President and
Chief Executive Officer of Applied BioTechnology, Inc.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing bioactive products to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements. Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, surgical
adhesives for use in the repair of damaged spinal discs and as sealants in
pulmonary, bowel and cardiovascular surgery, scaffolds for wound healing and
tissue engineering, and depots for local drug delivery. To date, PPTI has been
issued twenty-five U.S. Patents on its core technology with corresponding
issued and pending patents in key international markets.

    This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer
to the Company's 2003 Annual Report Form 10-KSB, and other recent filings with
the Securities and Exchange Commission, copies of which are available from the
Company, to further ascertain the risks associated with the above statements.

Link to this page: